Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 2.96 B
The data is delayed by 15 minutes.
CTLT is in the long-term up 70% in 5 years.
Description: Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment?s oral dose forms include soft gel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development & Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scient
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||124.71 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-14.05%||Sales Growth - Q/Q||-2.02%||P/E|
|P/E To EPS Growth||P/S||1.61||P/BV||6.33||Price/Cash Per Share|
|Price/Free Cash Flow||53.01||ROA||2.88%||ROE||18.13%||ROI||3.43%|
|Current Ratio||1.79||Quick Ratio||1.4||Long Term Debt/Equity||6.45||Debt Ratio||0.77|
|Gross Margin||33.9%||Operating Margin||14.77%||Net Profit Margin||4.66%||Dividend Payout Ratio|
|Cash From Financing Activities||209 M||Cash From Investing Activities||-240.3 M||Cash From Operating Activities||94.7 M||Gross Profit||152.2 M|
|Net Profit||31.5 M||Operating Profit||65.8 M||Total Assets||2.97 B||Total Current Assets||653.1 M|
|Total Current Liabilities||365.4 M||Total Debt||1.88 B||Total Liabilities||2.51 B||Total Revenue||446.6 M|
|High 52 week||46.34||Low 52 week||29.84||Last close||45.18||Last change||0.38%|
|RSI||72.59||Average true range||1.41||Beta||1.09||Volume||419.58 K|
|Simple moving average 20 days||7.41%||Simple moving average 50 days||7.09%||Simple moving average 200 days||12.72%|
|Performance Week||2.59%||Performance Month||11.47%||Performance Quart||23.81%||Performance Half||15.52%|
|Performance Year||9.34%||Performance Year-to-date||44.9%||Volatility daily||2.94%||Volatility weekly||6.57%|
|Volatility monthly||13.46%||Volatility yearly||46.63%||Relative Volume||271.85%||Average Volume||828.46 K|
|New High||New Low|
2019-06-10 08:06:38 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-30 16:15:00 | Catalent, Inc. to Present at the Jefferies Healthcare Conference
2019-05-30 08:04:59 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-28 08:05:07 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-21 08:52:12 | Catalent Acquires Gene Therapy Leader Paragon Bioservices
2019-05-08 08:31:01 | Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT
2019-05-07 14:23:34 | Catalent Inc CTLT Q3 2019 Earnings Call Transcript
2019-05-07 08:55:12 | Catalent CTLT Surpasses Q3 Earnings Estimates
2019-05-07 08:03:34 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-07 07:45:36 | Catalent: Fiscal 3Q Earnings Snapshot
2019-05-07 07:30:00 | Catalent, Inc. Reports Third Quarter Fiscal 2019 Results
2019-04-30 10:32:02 | Catalent CTLT Earnings Expected to Grow: What to Know Ahead of Next Week's Release
2019-04-24 10:52:31 | Did Hedge Funds Drop The Ball On Catalent Inc CTLT ?
2019-04-15 15:33:27 | Catalent seeks slice of gene therapy market with Paragon buy
2019-04-15 09:53:00 | Catalent to Buy Paragon Bioservices for $1.2 Billion
2019-04-15 09:27:11 | Catalent Agrees To Buy Gene Therapy-Focused CDMO Paragon Services For $1.2B
2019-04-15 08:12:08 | Stocks making the biggest moves premarket: Goldman Sachs, CVS, Best Buy, Facebook & more
2019-04-15 07:15:00 | Catalent to acquire Paragon Bioservices for $1.2 billion in cash
2019-04-15 07:13:41 | Catalent to buy Paragon Bioservices for $1.2 bln
2019-04-15 07:02:00 | Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
2019-04-14 23:17:33 | Catalent to buy Paragon Bioservices for $1.2 billion - WSJ
2019-04-14 19:42:09 | Catalent to buy Paragon Bioservices for $1.2 bln - WSJ
2019-04-14 19:39:19 | Catalent to buy Paragon Bioservices for $1.2 bln -WSJ
2019-04-11 07:13:13 | Update: Catalent NYSE:CTLT Stock Gained 34% In The Last Three Years
2019-04-09 16:15:00 | Catalent, Inc. Announces Third Quarter Fiscal Year 2019 Earnings Conference Webcast
2019-04-09 10:45:48 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-04-03 09:30:01 | CTLT or ORINY: Which Is the Better Value Stock Right Now?
2019-04-03 07:30:00 | Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience
2019-03-26 08:21:56 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-03-15 09:30:01 | CTLT or NBIX: Which Is the Better Value Stock Right Now?
2019-03-07 06:07:06 | Is Catalent, Inc.’s NYSE:CTLT Balance Sheet A Threat To Its Future?
2019-03-06 16:15:00 | Catalent, Inc. to Present at the Barclays Global Healthcare Conference
2019-03-04 23:40:04 | Champions Oncology CSBR Q3 Earnings: What's in Store?
2019-02-26 08:55:01 | 4 Drug Stocks to Buy Despite Price Hearing Woes
2019-02-15 08:16:01 | Will Catalent Continue to Surge Higher?
2019-02-13 07:00:00 | Catalent Names Alessandro Maselli President and Chief Operating Officer
2019-02-12 09:30:02 | CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
2019-02-08 08:07:11 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-02-05 14:50:57 | Edited Transcript of CTLT earnings conference call or presentation 5-Feb-19 1:15pm GMT
2019-02-05 12:55:19 | Catalent Inc CTLT Q2 2019 Earnings Conference Call Transcript
2019-02-05 08:55:01 | Catalent CTLT Beats Q2 Earnings and Revenue Estimates
2019-02-05 07:52:35 | Catalent: Fiscal 2Q Earnings Snapshot
2019-02-05 07:30:00 | Catalent, Inc. Reports Second Quarter Fiscal 2019 Results
2019-01-29 10:31:03 | Analysts Estimate Catalent CTLT to Report a Decline in Earnings: What to Look Out for
2019-01-29 08:03:11 | See what the IHS Markit Score report has to say about Catalent Inc.